Walgreen Company 8-K 2010
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 23, 2010
(Exact name of registrant as specified in its charter)
Registrant’s telephone number, including area code:(847) 940-2500
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
This amendment to the current report on Form 8-K/A filed by Walgreen Co. on March 24, 2010 (the “Original Report”) is being filed to clarify the scope of Stanley B. Blaylock’s non-competition restrictions.
On February 23, 2010, Stanley B. Blaylock, senior vice president of Walgreen Co. (the “Company”) and president of Walgreens Health Services, informed the Company that he will leave the Company in April after a transition period. Subsequently, the parties agreed on April 2, 2010 as the effective date of Mr. Blaylock’s separation from the Company (“Separation Date”).
Mr. Blaylock and the Company have entered into a Separation and Release Agreement to confirm the terms and conditions of Mr. Blaylock’s separation from the Company. The material terms and conditions of the Agreement are as follows:
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.